FDA panel backs Mass. company's ALS drug in rare, 2nd review
The Food and Drug Administration is not required to follow the panel's advice, but its positive recommendation suggests an approval is likely later this month.
Stay updated with breaking news from Billy Dunn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Food and Drug Administration is not required to follow the panel's advice, but its positive recommendation suggests an approval is likely later this month.
A panel of federal health advisers has voted to recommend approval for an experimental drug to treat Lou Gehrig’s disease
A panel of external advisers to the U.S. Food and Drug Administration (FDA) voted on Sept. 7 to recommend ...
Panel reverses its decision, paving the way for possible approval later this month
A panel of federal health advisers has voted to recommend approval for an experimental drug to treat Lou Gehrig's disease. The ruling Wednesday is a remarkable turnaround for the much-debated medication that was previously rejected by the same group earlier this year. The FDA previously held a meeting in March where the outside experts narrowly sided against Amylyx's drug, saying the company's data was unconvincing. Wednesday's meeting focused on new analyses which the company said strengthened its case for approval. Patients and their families have rallied behind Amylyx's drug, urging approva...